The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Becker et al., N Engl J Med 353(23):2450-2461 December 8, 2005.

Correspondence
PreviousPrevious
Volume 354:1532-1533 April 6, 2006 Number 14
NextNext

Febuxostat versus Allopurinol for Gout

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Becker, M. A.
-PubMed Citation
To the Editor: The article by Becker et al. (Dec. 8 issue)1 includes an inaccurate and misleading statement regarding the comparison of 80 mg per day of febuxostat with allopurinol for gout. The authors state that "the rates of discontinuation were similar in the 80-mg febuxostat and the allopurinol groups but were significantly higher in the 120-mg febuxostat group than in the other two groups (P=0.003)."

The authors do not present a statistical analysis comparing the rates of discontinuation in the 80-mg febuxostat group with those in the allopurinol group. On the basis of the data they present, there was . . . [Full Text of this Article]


This article has been cited by other articles:


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.